Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan

Therapeutic options for patients with castration-resistant prostate cancer (CRPC) remain limited. In a multicenter, Phase II study, 65 patients with histologically confirmed CRPC received a biomodulatory regimen during the six-month core study. Treatment comprised daily doses of imatinib mesylate, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Vogelhuber, M., Feyerabend, S., Stenzl, A., Suedhoff, T., Schulze, M., Huebner, J., Oberneder, R., Wieland, W., Mueller, S., Eichhorn, F., Heinzer, H., Schmidt, K., Baier, M., Ruebel, A., Birkholz, K., Bakhshandeh-Bath, A., Andreesen, R., Herr, W., Reichle, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449347/
https://www.ncbi.nlm.nih.gov/pubmed/25503648
http://dx.doi.org/10.1007/s12307-014-0161-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449347/
https://www.ncbi.nlm.nih.gov/pubmed/25503648
http://dx.doi.org/10.1007/s12307-014-0161-7

Ejemplares similares